drugset / Trial / NCT06714591

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

NCT06714591

Phase 1 Recruiting 120 enrolled SystImmune Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.

Timeline

Start
2024-12-19
Primary completion
2026-12-31
Completion
2027-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BL-M11D1 Unknown Intravenous